Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 4,859

Document Document Title
WO/2009/080637A1
Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; a...  
WO/2009/080722A3
The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: ...  
WO/2009/079375A1
Novel histone deacetylase inhibitors, including novel fluorescent histone deacetylase inhibitors, are described. Methods for making and using the same, e.g., to treat cancer, are provided.  
WO/2009/073427A1
The invention provides novel aryl and aliphatic esters of fluorinated alkanesulfonic acids. The invention also provides novel fluorinated alkanesulfonamides and a process to make the same. The invention also provides a process for the ar...  
WO/2009/071947A3
Compounds of formula (I) and pharmacologically acceptable salts wherein: Ar1 and Ar2 = aryl or heteroaryl; are excellent selective modulators of potassium ion flux.through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treat...  
WO/2009/071947A2
Compounds of formula (I) and pharmacologically acceptable salts wherein: Ar1 and Ar2 = aryl or heteroaryl; are excellent selective modulators of potassium ion flux.through KCNQ2, KCNQ3 and/or KCNQ2/3 channels, making them of use in treat...  
WO/2009/066035A3
Combination of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also pharmaceutical compositions containing same. Medicaments  
WO/2009/067597A1
Compounds of the formula: (I) are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.  
WO/2009/066035A2
Combination of an anti-atherothrombotic and an angiotensin-converting enzyme inhibitor (ACEI), and also pharmaceutical compositions containing same. Medicaments  
WO/2009/064449A1
Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including huma...  
WO/2009/064250A1
The invention provides compounds of formula wherein R1, R2 , R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for...  
WO/2009/064251A1
The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with pr...  
WO/2009/061652A8
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...  
WO/2009/061652A1
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating ...  
WO/2009/055917A1
ABSTRACT OF THE DISCLOSURE This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharm...  
WO/2009/053058A3
The invention relates to salts of 2-iodo-N-[(4-methoxy-6-methyl-1,3,5-triazine-2- yl)carbamoyl]benzenesulfonamide, to methods for the production thereof, and use thereof as herbicides, in particular as herbicides for selectively combatin...  
WO/2009/053763A8
The present invention relates to new non-peptide derivatives of formula (I), wherein R1 -R5, Q and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selecti...  
WO/2009/053058A2
The invention relates to salts of 2-iodo-N-[(4-methoxy-6-methyl-1,3,5-triazine-2- yl)carbamoyl]benzenesulfonamide, to methods for the production thereof, and use thereof as herbicides, in particular as herbicides for selectively combatin...  
WO/2009/053763A1
The present invention relates to new non-peptide derivatives of formula (I), wherein R1 -R5, Q and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selecti...  
WO/2009/053281A1
A process for the preparation of cyclopropyl sulfonamide of the formula (I) is described, comprising (a) the conversion of cyclopropane sulfonyl chloride with tert.-butylamine to form the N-tert.-butyl-3-chloropropyl sulfonamide; (b) sub...  
WO/2009/048653A1
The invention provides ion conducting copolymers containing pendant bis(aryl)sulfonimide groups that are used to make polymer electrolyte membranes (PEM's), catalyst coated proton exchange membranes (CCM's) and membrane electrode assembl...  
WO/2009/043784A1
Compounds of the formula (I) wherein Ar1, Ar2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.  
WO/2009/040517A3
The present invention pertains to the general field of chemical synthesis, and more particularly to methods for the synthesis of certain hydroxamic acid compounds, and in particular, (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide,...  
WO/2009/040289A3
The invention is concerned with novel biaryl sulfonamide derivatives of formula (I) wherein R1 to R3 and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compoun...  
WO/2009/042970A1
The invention relates to N-hydroxylsulfonamide derivatives for formula (I), (II) or (III), in which the variables are as defined in the claims, that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or p...  
WO/2009/042094A3
Compounds of Formula A are disclosed: (A), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6 and R7 are defined herein. The compounds encompassed by Formula A include compounds which are HIV protease inhibitors and other compounds which can be ...  
WO/2009/040289A2
The invention is concerned with novel biaryl sulfonamide derivatives of formula (I) wherein R1 to R3 and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compoun...  
WO/2009/040517A2
The present invention pertains to the general field of chemical synthesis, and more particularly to methods for the synthesis of certain hydroxamic acid compounds, and in particular, (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide,...  
WO/2009/042093A1
Compounds of Formula I are disclosed: (I), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6, R6A, R7 and R8 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds whic...  
WO/2009/038879A2
The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cell...  
WO/2009/038879A3
The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cell...  
WO/2009/037497A1
The present invention relates to a process for preparing a class of sulphonamides which are aspartyl protease inhibitors. These compounds find therapeutic use in the treatment of the human immunodeficiency virus (HIV). This virus is the ...  
WO/2009/039181A3
Organocatalysts, particularly proline sulfonamide organocatalysts, having a first general formula as follows are disclosed. Embodiments of a method for using these organocatalysts also are disclosed. The method comprises providing a disc...  
WO/2009/038204A1
It is intended to provide a novel long-chain fatty acid derivative compound having an agonistic activity to GPR120 and GPR40. The long-chain fatty acid derivative compound of the invention is represented by the following general formula ...  
WO/2009/037416A1
The present invention relates to a process for preparing a class of sulphonamides which are aspartyl protease inhibitors. These compounds find therapeutic use in the treatment of the human immunodeficiency virus (HIV). This virus is the ...  
WO/2009/034432A2
The invention relates to compounds of formula: (I) processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical compositions containing them.  
WO/2009/035928A1
Disclosed are amide, thoiamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and co...  
WO/2009/034432A8
The invention relates to compounds of formula: (I) processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical compositions containing them.  
WO/2009/034432A3
The invention relates to compounds of formula: (I) processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical compositions containing them.  
WO/2009/035855A3
The present invention relates to methods of treating disorders relating to mood, anxiety, stress, sleep, cognitive impairment/dysfunction, substance dependency/abuse, metabolism, eating and chronic pain comprising administering a therape...  
WO/2009/021944A1
The present invention relates to compounds of the general formula (I), wherein A, B, D, Y, R1, R2, R3, R4 and R5 are defined as mentioned in the description, the enantiomers, diastereomers, mixtures, and salts thereof, particularly physi...  
WO/2009/021945A1
The present invention relates to compounds of the general formula (I), wherein A1, A2, B, D, Y, R1, R2, R3, R4 and R5 are defined as mentioned in the description, the enantiomers, diastereomers, mixtures, and salts thereof, particularly ...  
WO/2009/022721A1
Disclosed is a compound represented by the general formula (I) below, which has retinoid action and is useful as an active ingredient of pharmaceutical products. (In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group; A and...  
WO/2009/022681A1
Disclosed is a positive resist composition which is good in pattern shape, line-edge roughness, pattern collapse, sensitivity and resolution in conventional exposure (dry exposure), liquid immersion exposure and double exposure. Also dis...  
WO/2009/016083A1
Disclosed are a method for improving the degradation of natural and/or synthetic polymers or a polymer article made from such polymer(s) by light and/or heat and/or humidity, comprising the incorporation of a compound of formula (I) into...  
WO/2009/013915A8
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...  
WO/2009/013915A1
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...  
WO/2009/012954A1
The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R...  
WO/2009/015028A1
Disclosed herein are deuterated derivatives of TAK-242 of Formula (I) which are modulators of TLR4 signalling pathway, pharmaceutical compositions thereof and methods of use thereof. Formula (I)  
WO/2009/012203A1
Methods for preparing compound of Formula (I) are described, wherein R1-R3 are defined herein, as are methods for preparing the intermediates formed therein. Formula (I) Also described are methods for enantioselectively preparing a chira...  

Matches 401 - 450 out of 4,859